Your browser doesn't support javascript.
loading
Acute Megakaryoblastic Leukemia Harboring a Subclone Expressing BCR-ABL1 Fusion Gene Product.
Kashima, Emiko; Nakano, Eri; Watanabe, Yasuyuki; Imai, Hiroshi; Oka, Koji; Kageyama, Shinichi; Tanaka, Isao.
Afiliação
  • Kashima E; Department of Hematology, Suzuka Kaisei Hospital, Japan.
  • Nakano E; Department of Hematology, Suzuka Kaisei Hospital, Japan.
  • Watanabe Y; Department of Hematology, Suzuka Kaisei Hospital, Japan.
  • Imai H; Pathology Division, Mie University Hospital, Japan.
  • Oka K; Department of Hematology, Suzuka Kaisei Hospital, Japan.
  • Kageyama S; Department of Hematology, Suzuka Kaisei Hospital, Japan.
  • Tanaka I; Department of Hematology, Suzuka Kaisei Hospital, Japan.
Intern Med ; 60(22): 3609-3614, 2021 Nov 15.
Article em En | MEDLINE | ID: mdl-34053988
ABSTRACT
Acute myeloid leukemia (AML) with BCR-ABL1, also termed Philadelphia chromosome-positive AML (Ph+ AML), is a rare leukemia subtype classified by the World Health Organization in 2016. The characteristics of Ph+ AML have not been fully identified yet. We herein report a patient with Ph+ AML who phenotypically exhibited megakaryoblastic characteristics, FABM7 and harbored a subclone expressing BCR-ABL1 gene fusion products. This case suggests that BCR-ABL1 was acquired as a subclone due to a secondary event that might have occurred late during leukemia evolution. Our findings may aid in deciphering the mechanism underlying Ph+ AML development in future studies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Leucemia Megacarioblástica Aguda Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Leucemia Megacarioblástica Aguda Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article